Results 11 to 20 of about 17,302 (216)

Hematologic improvements in a myelodysplastic syndromes with myelofibrosis (MDS-F) patient treated with azacitidine

open access: yesLeukemia Research Reports, 2014
Myelodysplastic syndromes with myelofibrosis (MDS-F) is a poor prognostic hematopoietic disorder. Azacitidine was shown to prolong survival of high-risk MDS patients. However, the effects of azacitidine on MDS-F have yet to be elucidated. Azacitidine was
Daisuke Okamura   +9 more
doaj   +2 more sources

Azacitidine as salvage therapy for acute myeloid leukemia in a severely ill patient

open access: yesHematology Reports, 2014
Acute myeloid leukemia (AML) is a hematological malignancy of myeloid progenitor cells that disrupt normal hematopoiesis. Current chemotherapy regimens result in complete remission in many cases; however, there exists no standard efficacious therapy for ...
Harry Ross Powers   +4 more
doaj   +2 more sources

Azacitidine-induced bullous pemphigoid-like localized toxic reaction [PDF]

open access: yesEinstein (São Paulo)
Azacitidine is a hypomethylating agent recommended for the treatment of patients with high-risk myelodysplastic syndromes. Here, we report the case of a patient with myelodysplastic syndrome who was not eligible for allogeneic stem cell transplantation ...
Rodrigo Brêtas Emerich Nogueira   +7 more
doaj   +3 more sources

Safety and efficacy of azacitidine in myelodysplastic syndromes

open access: yesDrug Design, Development and Therapy, 2010
Carlos E Vigil, Taida Martin-Santos, Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAPurpose: The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are ...
Carlos E Vigil   +2 more
doaj   +1 more source

Real‐world study of the use of azacitidine in myelodysplasia in Australia

open access: yeseJHaem
Hypomethylating agents are the most widely used upfront therapy for patients with myelodysplastic syndrome (MDS) who are not suitable for hematopoietic stem cell transplantation.
Anoop Enjeti   +7 more
doaj   +2 more sources

Rapid Onset Liver Injury Due to Azacitidine Through Possibly a Unique Mechanism of Hypoperfusion of the Liver

open access: yesJournal of Investigative Medicine High Impact Case Reports
Azacitidine and venetoclax are important anti-neoplastic agents used in the treatment of acute myeloid leukemia. Azacitidine has been implicated to cause nonhepatic ischemic injury. Here we report a case of severe, short latency drug-induced liver injury
Dilara Hatipoglu MD   +3 more
doaj   +2 more sources

Cytomegalovirus Colitis Following Azacitidine Therapy [PDF]

open access: yesCanadian Journal of Infectious Diseases and Medical Microbiology, 2011
The present report describes the first recognized case of cytomegalovirus (CMV) colitis following azacitidine therapy. A 66-year-old woman with myelodysplastic syndrome developed CMV colitis, which responded to treatment with ganciclovir.
Rajal Khan   +6 more
doaj   +2 more sources

The role of azacitidine in the management of myelodysplastic syndromes (MDS)

open access: yesCancer Management and Research, 2009
KS Götze, C Müller-Thomas, C PeschelDepartment of Medicine, Hematology/Oncology, Technische Universität München, Munich, GermanyAbstract: Myelodysplastic syndromes (MDS) are a group of common bone marrow disorders ...
KS Götze   +2 more
doaj   +1 more source

Thrombocytopenia between azacitidine monotherapy vs azacitidine combination.

open access: yes, 2022
Thrombocytopenia between azacitidine monotherapy vs azacitidine combination.
Romina Brignardello-Petersen (814592)   +7 more
core   +1 more source

Azacitidine for the treatment of lower risk myelodysplastic syndromes : a retrospective study of 74 patients enrolled in an Italian named patient program. [PDF]

open access: yes, 2010
BACKGROUND: Azacitidine induces responses and prolongs overall survival compared with conventional care regimens in patients who have high-risk myelodysplastic syndromes (MDS).
RIVELLINI F   +10 more
core   +1 more source

Home - About - Disclaimer - Privacy